surpass cvot tirzepatide results In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx EASD's Video on X
Pay in 4 interest-free payments of $5.53 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25












:max_bytes(150000):strip_icc()/GettyImages-1259158436-1a2fd7f2794d4b4a9bedca6422346548.jpg)












